Prognostic impact of elevated C-reactive protein and procalcitonin in patients with extensive-stage small cell lung cancer
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Elevated C-reactive protein (CRP) and procalcitonin (PCT) levels in extensive-stage small cell lung cancer (SCLC) patients may indicate malignancy, not just infection. Higher PCT and CRP levels correlate with shorter progression-free and overall survival in SCLC.
Area Of Science
- Oncology
- Biomarkers
- Inflammation
Background
- Small cell lung cancer (SCLC) is a leading cause of cancer mortality globally.
- Inflammation markers like C-reactive protein (CRP) and procalcitonin (PCT) are typically associated with infection.
- Their role in non-infectious conditions like malignancy requires further investigation.
Purpose Of The Study
- To evaluate CRP and PCT levels in newly diagnosed extensive-stage SCLC patients without infection.
- To determine if elevated CRP and PCT can be indicators of malignancy.
- To correlate these inflammation markers with patient and disease characteristics for prognosis.
Main Methods
- Retrospective analysis of 115 extensive-stage SCLC patients diagnosed between January 2020 and December 2022.
- Measurement of C-reactive protein (CRP) and procalcitonin (PCT) levels at diagnosis.
- Kaplan-Meier analysis to assess progression-free survival (PFS) and overall survival (OS).
Main Results
- Patients with elevated procalcitonin (PCT) showed significantly shorter median PFS (6.73 months) and OS (9.10 months) compared to those with normal PCT (PFS: 7.86 months, OS: 11.66 months).
- Elevated CRP levels were also found to correlate with a poorer prognosis in extensive-stage SCLC.
- These findings suggest PCT and CRP elevation may reflect malignancy rather than infection.
Conclusions
- Elevated procalcitonin (PCT) and C-reactive protein (CRP) levels are associated with worse survival outcomes in extensive-stage small cell lung cancer (SCLC).
- These markers may serve as prognostic indicators in SCLC patients, even in the absence of infection.
- Further research is warranted to explore the mechanisms behind inflammation in SCLC and its impact on disease progression.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
• Pleurisy: indicates the inflammation of the pleura, which causes chest pain and discomfort.
• Pleural Effusion: indicates fluid buildup in the pleural space.
• Atelectasis: Partial collapse of a lung lobe due to mucus blockage or external compression.
• Bacteremia: Bacterial infection entering the bloodstream, commonly seen with...
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...